CelLBxHealth (CLBX) Q1 2026 TU earnings summary

Executive summary

• Q1 2026 focused on organizational restructuring and cost-saving measures to align with a revised business strategy.

• Headcount reduced from 44 to 39 FTEs in Q1, following a 60% reduction last year.

• Annual cash operating costs reduced by over £6.6 million, with further Q2 savings of £0.1 million identified.

• Cash at 31 March 2026 stood at £4.3 million, reflecting one-off restructuring costs.

Outlook and guidance

• Revenue for FY 2026 expected to reach at least £2.1 million, a 50% increase over FY 2025.

• Additional sales pipeline opportunities could further increase revenue guidance for the year.

• Board remains confident in delivering significant growth in 2026 and beyond.

Significant events and developments

• New head of sales appointed in the US to drive commercial progress.

• Advanced discussions underway with a major US healthcare provider for clinical studies using the Parsortix® platform.

• Final stages of a Master Services Agreement with a top ten global pharmaceutical company for Parsortix® platform use.

• Sub-lease agreement completed for part of the US facility.